美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

新橋生物

1.77

-0.0100-0.56%

盤後：1.770.00000.00%19:13 EDT

成交量：80.99萬

成交額：145.03萬

市值：2.04億

市盈率：-3.66

高：1.82

開：1.78

低：1.76

收：1.78

52周最高：6.79

52周最低：0.9800

股本：1.15億

流通股本：4,823.40萬

量比：0.84

換手率：1.68%

股息：- -

股息率：- -

每股收益(TTM):-0.4830

每股收益(LYR):-0.9225

淨資產收益率：-40.89%

總資產收益率：-24.90%

市淨率：0.88

市盈率(LYR):-1.92

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

新橋生物：預計最早於2026年第四季度啓動註冊性三期聯合試驗

新橋生物：FDA確認Givastomig有望符合加速審批資格

新橋生物計劃於2026年第四季度啓動以客觀緩解率為主要終點的註冊性三期聯合試驗

新橋生物宣佈與FDA就胃腺癌藥物Givastomig加速審批路徑達成建設性B類會議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NBP"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"新橋生物","latestPrice":1.77,"timestamp":1779480000000,"preClose":1.78,"halted":0,"volume":809936,"hourTrading":{"tag":"盘后","latestPrice":1.77,"preClose":1.77,"latestTime":"19:13 EDT","volume":294,"amount":520.57,"timestamp":1779491599911,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.005617977528089893,"floatShares":48234000,"shares":115266053,"eps":-0.483,"marketStatus":"休市中","change":-0.01,"latestTime":"05-22 16:00:00 EDT","open":1.78,"high":1.82,"low":1.76,"amount":1450303.9610271999,"amplitude":0.033708,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.483,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.78,"preHourTrading":{"tag":"盘前","latestPrice":1.78,"preClose":1.78,"latestTime":"09:09 EDT","volume":13292,"amount":23437.334330399997,"timestamp":1779455380051,"change":0,"changeRate":0,"amplitude":0.02764},"postHourTrading":{"tag":"盘后","latestPrice":1.77,"preClose":1.77,"latestTime":"19:13 EDT","volume":294,"amount":520.57,"timestamp":1779491599911,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8351245248522292,"impliedVol":0.9458,"impliedVolPercentile":0.4043},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":48234000,"roa":"-24.90%","roe":"-40.89%","lyrEps":-0.922468,"volumeRatio":0.8351245248522292,"shares":115266053,"dividePrice":0,"high":1.82,"amplitude":0.033708,"preClose":1.78,"low":1.76,"week52Low":0.98,"pbRate":"0.88","week52High":6.79,"institutionHeld":0,"latestPrice":1.77,"eps":-0.483,"divideRate":0,"volume":809936,"delay":0,"ttmEps":-0.483,"open":1.78,"prevYearClose":3.98,"prevWeekClose":1.82,"prevMonthClose":2.47,"prevQuarterClose":2.46,"fiveDayClose":1.82,"twentyDayClose":2.45,"sixtyDayClose":3.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-04-07","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1775534400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"NBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-05-22","current":-3.664596,"percent":0.978417,"low":-20.276437,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"high":-2.199338,"avg":-11.47101,"sd":5.199537,"marketCap":205854337},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129},{"date":"2026-04-02","current":-10.773226,"twenty":-16.597774,"median":-14.101539,"eighty":-11.587135,"marketCap":283615936},{"date":"2026-04-10","current":-3.171352,"twenty":-16.387565,"median":-14.057746,"eighty":-11.527134,"marketCap":280157205},{"date":"2026-04-17","current":-3.495376,"twenty":-16.299978,"median":-13.61981,"eighty":-11.287368,"marketCap":308781505},{"date":"2026-04-24","current":-3.23355,"twenty":-16.221149,"median":-13.10038,"eighty":-11.118286,"marketCap":285651804},{"date":"2026-05-01","current":-3.23355,"twenty":-16.203632,"median":-12.875318,"eighty":-11.061844,"marketCap":285651804},{"date":"2026-05-08","current":-2.906268,"twenty":-16.133562,"median":-12.604261,"eighty":-10.634902,"marketCap":256739678},{"date":"2026-05-15","current":-2.513529,"twenty":-16.045975,"median":-12.365376,"eighty":-3.526795,"marketCap":222045127},{"date":"2026-05-22","current":-2.330251,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"marketCap":205854337}],"updateTime":1779680128025},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1164386189","title":"新橋生物：預計最早於2026年第四季度啓動註冊性三期聯合試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1164386189","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164386189?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 20:42","pubTimestamp":1773664949,"startTime":"0","endTime":"0","summary":"新桥生物宣布，公司计划最早在2026年第四季度开展一项注册性三期联合临床试验。这一关键进展标志着其在创新疗法开发道路上迈出重要一步，为后续商业化布局奠定基础。通过将不同治疗机制相结合，该试验旨在探索更优临床效果，为患者提供突破性治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120501405","title":"新橋生物：FDA確認Givastomig有望符合加速審批資格","url":"https://stock-news.laohu8.com/highlight/detail?id=1120501405","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120501405?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 20:39","pubTimestamp":1773664740,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式确认，新桥生物（NovaBridge Biosciences）旗下在研药物Givastomig具备潜在资格，有望通过加速审批通道推进上市进程。\n这一进展意味着，若后续临床试验数据积极，Givastomig或可基于替代终点提前获批，从而缩短其进入市场的时间。加速审批路径通常适用于针对严重疾病、且现有治疗选择有限的创新疗法。\n新桥生物表示，将继续与FDA保持密切沟通，积极推进Givastomig的临床开发计划，以期早日为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139570168","title":"新橋生物計劃於2026年第四季度啓動以客觀緩解率為主要終點的註冊性三期聯合試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1139570168","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139570168?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:03","pubTimestamp":1773658990,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，公司将于2026年第四季度正式启动一项注册性三期联合疗法临床试验。该试验将采用客观缓解率（ORR）作为主要疗效终点，旨在评估创新疗法组合在目标患者群体中的治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106527073","title":"新橋生物宣佈與FDA就胃腺癌藥物Givastomig加速審批路徑達成建設性B類會議","url":"https://stock-news.laohu8.com/highlight/detail?id=1106527073","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106527073?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:02","pubTimestamp":1773658924,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）近日披露，该公司与美国食品药品监督管理局（FDA）针对其在研药物Givastomig用于治疗胃腺癌的加速批准路径，成功举行了一场富有成效的B类会议。\n此次会议重点探讨了Givastomig通过加速审批通道上市的可能性，双方就后续临床开发策略及数据要求达成重要共识。该进展标志着Givastomig在胃腺癌治疗领域的商业化进程迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NBP\",params:#limit:6,delay:false,,,undefined,":[]}}